Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.774 -0.066 (-3.59%)
Streaming Delayed Price Updated: 9:41 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
News headline image
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy ↗
Photo by Daniil Kuželev on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed ↗
Lineage Cell Therapeutics (AMEX:LCTX) brought in sales totaling $512.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 0.43%, resulting... 
Via Benzinga
News headline image
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021
From Lineage Cell Therapeutics
Via Business Wire
News headline image
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
38 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of... 
Via Benzinga
Topics Intellectual Property
News headline image
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
53 Biggest Movers From Yesterday ↗
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation... 
Via Benzinga
Topics Initial Public Offering
News headline image
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Appointment of General Counsel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Call Transcript ↗
LCTX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game? ↗
Image by Rudy and Peter Skitterians from Pixabay Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to... 
Via Benzinga
News headline image
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements ↗
Lineage Cell Therapeutics Inc (NYSE: LCTX) reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell therapy for dry... 
Via Benzinga
News headline image
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.